carvedilol has been researched along with Cruveilhier-Baumgarten Syndrome in 55 studies
Cruveilhier-Baumgarten Syndrome: Liver cirrhosis with intrahepatic portal obstruction, HYPERTENSION, and patent UMBILICAL VEINS.
| Excerpt | Relevance | Reference |
|---|---|---|
| " The aim of this randomized study was to evaluate and compare the effects of carvedilol and nebivolol on the hepatic venous pressure gradient (HVPG) response in the patients with liver cirrhosis." | 9.17 | Acute and 14-day hepatic venous pressure gradient response to carvedilol and nebivolol in patients with liver cirrhosis. ( Jonaitis, L; Kupčinskas, J; Kupčinskas, L; Petrenkienė, V; Pranculis, A; Silkauskaitė, V, 2013) |
| "In this prospective cohort study, 106 cirrhotic patients with high-risk esophageal varices in the derivation cohort received carvedilol prophylaxis, and completed paired measurements of hepatic venous pressure gradient, liver stiffness (LS), and spleen stiffness (SS) at the beginning and end of dose titration." | 7.91 | Non-invasive response prediction in prophylactic carvedilol therapy for cirrhotic patients with esophageal varices. ( Ahn, DW; Baik, SK; Jung, YJ; Kim, D; Kim, HY; Kim, MY; Kim, W; So, YH; Woo, H, 2019) |
| "Propranolol has been used as prophylaxis for variceal bleeding in patients with cirrhosis." | 6.82 | A Randomized, Multi-Center, Open-Label Study to Evaluate the Efficacy of Carvedilol vs. Propranolol to Reduce Portal Pressure in Patients With Liver Cirrhosis. ( Baik, SK; Jang, JY; Jeong, SW; Kim, DJ; Kim, MY; Kim, SG; Kim, TY; Kim, YS; Lee, B; Seo, YS; Sohn, JH; Suk, KT; Um, SH, 2016) |
| "Liver cirrhosis was induced in rats by carbon tetrachloride (CCl4) administration for 9 weeks; carvedilol was administered simultaneously in the experimental group." | 5.51 | Carvedilol improves liver cirrhosis in rats by inhibiting hepatic stellate cell activation, proliferation, invasion and collagen synthesis. ( Li, G; Li, Z; Ling, L; Meng, D; Wang, G; Zhang, C, 2019) |
| "Cirrhotic patients with esophageal varices were randomized to carvedilol 12." | 5.19 | Carvedilol vs. esophageal variceal band ligation in the primary prophylaxis of variceal hemorrhage: a multicentre randomized controlled trial. ( Abid, S; Azam, Z; Hamid, S; Ismail, FW; Jafri, W; Khalid, A; Munir, SM; Parkash, O; Rauf, J; Shah, HA; Subhan, A, 2014) |
| " The aim of this randomized study was to evaluate and compare the effects of carvedilol and nebivolol on the hepatic venous pressure gradient (HVPG) response in the patients with liver cirrhosis." | 5.17 | Acute and 14-day hepatic venous pressure gradient response to carvedilol and nebivolol in patients with liver cirrhosis. ( Jonaitis, L; Kupčinskas, J; Kupčinskas, L; Petrenkienė, V; Pranculis, A; Silkauskaitė, V, 2013) |
| "In this prospective cohort study, 106 cirrhotic patients with high-risk esophageal varices in the derivation cohort received carvedilol prophylaxis, and completed paired measurements of hepatic venous pressure gradient, liver stiffness (LS), and spleen stiffness (SS) at the beginning and end of dose titration." | 3.91 | Non-invasive response prediction in prophylactic carvedilol therapy for cirrhotic patients with esophageal varices. ( Ahn, DW; Baik, SK; Jung, YJ; Kim, D; Kim, HY; Kim, MY; Kim, W; So, YH; Woo, H, 2019) |
| "BACKGROUND Carvedilol is the first-line drug for the primary prophylaxis of variceal bleeding due to portal hypertension (PHT) in liver cirrhosis." | 3.88 | Carvedilol Ameliorates Intrahepatic Angiogenesis, Sinusoidal Remodeling and Portal Pressure in Cirrhotic Rats. ( Li, G; Ling, L; Meng, D; Wang, S; Zhang, C, 2018) |
| " The aim of study was to assess the correlation between the therapeutic efficacy of carvedilol and markers of endothelial dysfunction and systemic inflammation in patients with liver cirrhosis and portal hypertension." | 3.73 | Effect of carvedilol on portal hypertension depends on the degree of endothelial activation and inflammatory changes. ( Bruha, R; Dousa, M; Jachymova, M; Kalab, M; Lenicek, M; Marecek, Z; Petrtyl, J; Svestka, T; Urbanek, P; Vitek, L; Zelenka, J, 2006) |
| "Portal hypertension is the primary driver of decompensation, including the development of ascites, hepatic encephalopathy and variceal haemorrhage." | 3.01 | Review article: controversies surrounding the use of carvedilol and other beta blockers in the management of portal hypertension and cirrhosis. ( Gillespie, SL; Hanrahan, TP; Hayes, PC; Majumdar, A; Rockey, DC, 2023) |
| "Carvedilol is a non-selective beta-blocker (NSBB) acting on hyperdynamic circulation/splanchnic vasodilation and on intrahepatic resistance." | 3.01 | Carvedilol as the new non-selective beta-blocker of choice in patients with cirrhosis and portal hypertension. ( La Mura, V; Reiberger, T; Turco, L; Vitale, G, 2023) |
| "Propranolol has been used as prophylaxis for variceal bleeding in patients with cirrhosis." | 2.82 | A Randomized, Multi-Center, Open-Label Study to Evaluate the Efficacy of Carvedilol vs. Propranolol to Reduce Portal Pressure in Patients With Liver Cirrhosis. ( Baik, SK; Jang, JY; Jeong, SW; Kim, DJ; Kim, MY; Kim, SG; Kim, TY; Kim, YS; Lee, B; Seo, YS; Sohn, JH; Suk, KT; Um, SH, 2016) |
| "Carvedilol has been shown to be more effective than propranolol in decreasing portal pressure." | 2.77 | Randomized, controlled trial of carvedilol versus nadolol plus isosorbide mononitrate for the prevention of variceal rebleeding. ( Chen, WC; Lo, GH; Wang, HM; Yu, HC, 2012) |
| "Carvedilol is an option for primary prophylaxis in patients with high-risk esophageal varices." | 2.74 | Randomized controlled trial of carvedilol versus variceal band ligation for the prevention of the first variceal bleed. ( Ferguson, JW; Forrest, EH; Hayes, PC; Hislop, WS; Kochar, N; Leithead, JA; McAvoy, NC; Mills, PR; Stanley, AJ; Therapondos, G; Tripathi, D, 2009) |
| "Carvedilol is a nonselective beta-blocker with alpha(1)-adrenergic blocking activity." | 2.71 | Acute administration of carvedilol is more effective than propranolol plus isosorbide-5-mononitrate in the reduction of portal pressure in patients with viral cirrhosis. ( Hou, MC; Huang, YT; Lee, FY; Lee, SD; Lin, HC; Yang, YY, 2004) |
| "Portal hypertension is the result of increased hepatic resistance and portal influx." | 2.71 | The effects of carvedilol a nonselective beta-blocker on portal hemodynamics in cirrhosis. ( Andronescu, D; Dragomir, P; Fierbinteanu-Braticevici, C; Udeanu, M, 2003) |
| "Short-term carvedilol administration is more powerful than propranolol in decreasing hepatic venous pressure gradient (HVPG) in cirrhotic patients, but induces arterial hypotension that may prevent its long-term use in portal hypertensive patients." | 2.70 | Randomized comparison of long-term carvedilol and propranolol administration in the treatment of portal hypertension in cirrhosis. ( Abraldes, JG; Albillos, A; Bañares, R; Bosch, J; De Diego, A; García-Pagán, JC; Lampreave, JL; Matilla, A; Moitinho, E; Piera, C, 2002) |
| " Chronic administration resulted in a further fall in the hepatic venous pressure gradient from a baseline of 16." | 2.70 | Haemodynamic effects of acute and chronic administration of low-dose carvedilol, a vasodilating beta-blocker, in patients with cirrhosis and portal hypertension. ( Hayes, PC; Lui, HF; Stanley, AJ; Therapondos, G; Tripathi, D, 2002) |
| "Carvedilol is a relatively safe, effective portal hypotensive agent, both acutely and over 7 days, but not superior to propranolol, at least in Indians." | 2.70 | Acute and 7-day portal pressure response to carvedilol and propranolol in cirrhotics. ( Biswas, PK; Das, D; De, BK; Maity, AK; Majumdar, D; Mandal, SK; Sen, S, 2002) |
| "Recent advances in the pharmacologic treatment of portal hypertension have mainly focused on modifying an increased intrahepatic resistance through nitric oxide and/or modulation of vasoactive substances." | 2.61 | Pharmacologic Management of Portal Hypertension. ( Bunchorntavakul, C; Reddy, KR, 2019) |
| "Once gastroesophageal varices have developed, non-selective beta-blockers remain the cornerstone of therapy." | 2.55 | Prevention and treatment of variceal haemorrhage in 2017. ( Berzigotti, A; Bosch, J; Brunner, F, 2017) |
| "Carvedilol is a nonselective beta-blocker with a mild anti-alfa-1-adrenergic activity." | 2.50 | Systematic review with meta-analysis: the haemodynamic effects of carvedilol compared with propranolol for portal hypertension in cirrhosis. ( D'Amico, G; D'Amico, M; Perricone, G; Sinagra, E; Tinè, F, 2014) |
| "Development of bleeding gastroesophageal varices is a serious consequence of portal hypertension secondary to cirrhosis." | 2.42 | Evaluation of carvedilol for the treatment of portal hypertension. ( Hemstreet, BA, 2004) |
| "Treatment of portal hypertension is evolving based on randomised controlled trials." | 2.42 | Management of portal hypertension. ( Burroughs, AK; Patch, DW; Samonakis, DN; Thalheimer, U; Triantos, CK, 2004) |
| "Presence and size of esophagogastric varices had an inverse relation to SDANN and SD of the NN intervals." | 1.91 | Heart rate variability is associated with disease severity and portal hypertension in cirrhosis. ( Amodio, E; Basso, MG; Cabibbo, G; Calvaruso, V; Casuccio, A; Craxì, A; Daidone, M; Di Raimondo, D; Licata, M; Miceli, G; Pennisi, G; Petta, S; Pinto, A; Pintus, C; Simone, F; Tuttolomondo, A; Velardo, M, 2023) |
| "Although liver cirrhosis complicated with chylothorax is rare, several case reports have shown all patients with chylothorax caused by liver cirrhosis were transudative." | 1.72 | [Transudative chylothorax complicated with liver cirrhosis due to primary biliary cholangitis:case report]. ( Higashizawa, T; Hisatake, Y; Kitagawa, K; Kondo, M; Noda, M; Okamura, Y; Sekine, C; Sunaga, S; Teramoto, K, 2022) |
| "Carvedilol was shown to have a positive effect on gastric varices without significant adverse effects." | 1.56 | CARVEDILOL AS PRIMARY PROPHYLAXIS FOR GASTRIC VARICEAL BLEEDING IN PORTAL HYPERTENSION MODEL IN RATS. ( Bertoldi, AS; Brighenti, LMV; Coltro, GA; Fauat, NI; Guetter, CR; Kubrusly, FB; Kubrusly, LF; Marques, CAM; Vosgerau, LM, 2020) |
| "Liver cirrhosis was induced in rats by carbon tetrachloride (CCl4) administration for 9 weeks; carvedilol was administered simultaneously in the experimental group." | 1.51 | Carvedilol improves liver cirrhosis in rats by inhibiting hepatic stellate cell activation, proliferation, invasion and collagen synthesis. ( Li, G; Li, Z; Ling, L; Meng, D; Wang, G; Zhang, C, 2019) |
| "Carvedilol 12." | 1.48 | Carvedilol for reducing portal pressure in primary prophylaxis of variceal bleeding: a dose-response study. ( Ferlitsch, A; Kivaranovic, D; Mandorfer, M; Paternostro, R; Peck-Radosavljevic, M; Reiberger, T; Schwarzer, R; Trauner, M, 2018) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (5.45) | 18.2507 |
| 2000's | 11 (20.00) | 29.6817 |
| 2010's | 30 (54.55) | 24.3611 |
| 2020's | 11 (20.00) | 2.80 |
| Authors | Studies |
|---|---|
| Jindal, A | 2 |
| Sarin, SK | 2 |
| Kumar, M | 1 |
| Kumar, G | 1 |
| Sunaga, S | 1 |
| Okamura, Y | 1 |
| Kondo, M | 1 |
| Kitagawa, K | 1 |
| Noda, M | 1 |
| Hisatake, Y | 1 |
| Teramoto, K | 1 |
| Higashizawa, T | 1 |
| Sekine, C | 1 |
| Villanueva, C | 3 |
| Torres, F | 2 |
| Shah, HA | 2 |
| Tripathi, D | 6 |
| Brujats, A | 1 |
| Rodrigues, SG | 1 |
| Bhardwaj, A | 1 |
| Azam, Z | 2 |
| Hayes, PC | 7 |
| Abid, S | 2 |
| Alvarado, E | 2 |
| Bosch, J | 8 |
| Gillespie, SL | 1 |
| Hanrahan, TP | 1 |
| Rockey, DC | 1 |
| Majumdar, A | 1 |
| Miceli, G | 1 |
| Calvaruso, V | 1 |
| Casuccio, A | 1 |
| Pennisi, G | 1 |
| Licata, M | 1 |
| Pintus, C | 1 |
| Basso, MG | 1 |
| Velardo, M | 1 |
| Daidone, M | 1 |
| Amodio, E | 1 |
| Petta, S | 1 |
| Simone, F | 1 |
| Cabibbo, G | 1 |
| Di Raimondo, D | 1 |
| Craxì, A | 1 |
| Pinto, A | 1 |
| Tuttolomondo, A | 1 |
| Turco, L | 1 |
| Reiberger, T | 6 |
| Vitale, G | 1 |
| La Mura, V | 1 |
| Bunchorntavakul, C | 1 |
| Reddy, KR | 1 |
| El Shahawy, MS | 1 |
| Shady, ZM | 1 |
| Gaafar, A | 1 |
| Huang, X | 1 |
| Fan, X | 1 |
| Chen, S | 1 |
| Bertoldi, AS | 1 |
| Guetter, CR | 1 |
| Coltro, GA | 1 |
| Vosgerau, LM | 1 |
| Brighenti, LMV | 1 |
| Fauat, NI | 1 |
| Kubrusly, FB | 1 |
| Marques, CAM | 1 |
| Kubrusly, LF | 1 |
| Ttl Tjwa, E | 1 |
| McDonald, N | 1 |
| Lilburn, DML | 1 |
| Lachlan, NJ | 1 |
| Macnaught, G | 1 |
| Patel, D | 1 |
| Jayaswal, ANA | 1 |
| Semple, SI | 1 |
| Fallowfield, JA | 1 |
| Püspök, A | 1 |
| Schoder, M | 1 |
| Baumann-Durchschein, F | 1 |
| Bucsics, T | 1 |
| Datz, C | 1 |
| Dolak, W | 1 |
| Ferlitsch, A | 4 |
| Finkenstedt, A | 1 |
| Graziadei, I | 1 |
| Hametner, S | 1 |
| Karnel, F | 1 |
| Krones, E | 1 |
| Maieron, A | 1 |
| Mandorfer, M | 3 |
| Peck-Radosavljevic, M | 3 |
| Rainer, F | 1 |
| Schwabl, P | 1 |
| Stadlbauer, V | 1 |
| Stauber, R | 1 |
| Tilg, H | 1 |
| Trauner, M | 2 |
| Zoller, H | 1 |
| Schöfl, R | 1 |
| Fickert, P | 1 |
| Baiges, A | 1 |
| Hernández-Gea, V | 1 |
| Sarkar, R | 1 |
| Paul, R | 1 |
| Roy, D | 1 |
| Saha, A | 1 |
| Sau, TJ | 1 |
| Mondal, J | 1 |
| Schwarzer, R | 1 |
| Kivaranovic, D | 1 |
| Paternostro, R | 1 |
| Stanley, AJ | 3 |
| Kim, HY | 1 |
| So, YH | 1 |
| Kim, W | 1 |
| Ahn, DW | 1 |
| Jung, YJ | 1 |
| Woo, H | 1 |
| Kim, D | 1 |
| Kim, MY | 2 |
| Baik, SK | 2 |
| Ling, L | 2 |
| Li, G | 2 |
| Meng, D | 2 |
| Wang, S | 1 |
| Zhang, C | 2 |
| Albillos, A | 2 |
| Genescà, J | 1 |
| Garcia-Pagan, JC | 3 |
| Calleja, JL | 1 |
| Aracil, C | 1 |
| Bañares, R | 3 |
| Morillas, RM | 1 |
| Poca, M | 1 |
| Peñas, B | 1 |
| Augustin, S | 1 |
| Abraldes, JG | 2 |
| Wang, G | 1 |
| Li, Z | 1 |
| Hobolth, L | 2 |
| Bendtsen, F | 2 |
| Hansen, EF | 1 |
| Møller, S | 2 |
| Rauf, J | 1 |
| Hamid, S | 1 |
| Jafri, W | 1 |
| Khalid, A | 1 |
| Ismail, FW | 1 |
| Parkash, O | 1 |
| Subhan, A | 1 |
| Munir, SM | 1 |
| Sinagra, E | 1 |
| Perricone, G | 1 |
| D'Amico, M | 1 |
| Tinè, F | 1 |
| D'Amico, G | 1 |
| Berzigotti, A | 2 |
| Silkauskaitė, V | 1 |
| Kupčinskas, J | 1 |
| Pranculis, A | 1 |
| Jonaitis, L | 1 |
| Petrenkienė, V | 1 |
| Kupčinskas, L | 1 |
| Li, T | 1 |
| Ke, W | 1 |
| Sun, P | 1 |
| Chen, X | 1 |
| Belgaumkar, A | 1 |
| Huang, Y | 1 |
| Xian, W | 1 |
| Li, J | 1 |
| Zheng, Q | 1 |
| Kim, SG | 1 |
| Kim, TY | 1 |
| Sohn, JH | 1 |
| Um, SH | 1 |
| Seo, YS | 1 |
| Jang, JY | 1 |
| Jeong, SW | 1 |
| Lee, B | 1 |
| Kim, YS | 1 |
| Suk, KT | 1 |
| Kim, DJ | 1 |
| Brunner, F | 1 |
| Steib, CJ | 1 |
| Gerbes, AL | 1 |
| Ferguson, JW | 1 |
| Kochar, N | 1 |
| Leithead, JA | 1 |
| Therapondos, G | 2 |
| McAvoy, NC | 1 |
| Forrest, EH | 2 |
| Hislop, WS | 1 |
| Mills, PR | 1 |
| Tsochatzis, EA | 1 |
| Triantos, CK | 2 |
| Burroughs, AK | 2 |
| Wang, CC | 1 |
| Kao, JH | 1 |
| Hussain, Q | 1 |
| Badruddin, AH | 1 |
| Chaudhry, MA | 1 |
| Ahmad, F | 1 |
| Abbasi, A | 1 |
| Payer, BA | 1 |
| Pinter, M | 1 |
| Homoncik, M | 1 |
| Grønbæk, H | 1 |
| Roelsgaard, K | 1 |
| Feldager Hansen, E | 1 |
| Lo, GH | 1 |
| Chen, WC | 1 |
| Wang, HM | 1 |
| Yu, HC | 1 |
| Moitinho, E | 2 |
| Matilla, A | 1 |
| Lampreave, JL | 1 |
| Piera, C | 1 |
| De Diego, A | 2 |
| Hemstreet, BA | 1 |
| Lin, HC | 1 |
| Yang, YY | 1 |
| Hou, MC | 1 |
| Huang, YT | 1 |
| Lee, FY | 1 |
| Lee, SD | 1 |
| Fierbinteanu-Braticevici, C | 1 |
| Udeanu, M | 1 |
| Dragomir, P | 1 |
| Andronescu, D | 1 |
| Samonakis, DN | 1 |
| Thalheimer, U | 1 |
| Patch, DW | 1 |
| Bruha, R | 1 |
| Vitek, L | 1 |
| Petrtyl, J | 1 |
| Lenicek, M | 1 |
| Urbanek, P | 1 |
| Zelenka, J | 1 |
| Jachymova, M | 1 |
| Svestka, T | 1 |
| Kalab, M | 1 |
| Dousa, M | 1 |
| Marecek, Z | 1 |
| Bouchier, IA | 1 |
| Sekiyama, T | 1 |
| Komeichi, H | 1 |
| Nagano, T | 1 |
| Ohsuga, M | 1 |
| Terada, H | 1 |
| Katsuta, Y | 1 |
| Satomura, K | 1 |
| Aramaki, T | 1 |
| Piqueras, B | 1 |
| Casado, M | 1 |
| Wong, F | 1 |
| Blendis, L | 1 |
| Lui, HF | 1 |
| De, BK | 1 |
| Das, D | 1 |
| Sen, S | 1 |
| Biswas, PK | 1 |
| Mandal, SK | 1 |
| Majumdar, D | 1 |
| Maity, AK | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Prospective Multicenter Cohort Study on the Timing of Emergency Endoscopy for Esophagogastric Variceal Bleeding in Cirrhosis[NCT04932200] | 608 participants (Anticipated) | Observational | 2021-06-15 | Not yet recruiting | |||
| Timing of Endoscopic Intervention in Patients With Cirrhosis With Acute Variceal Upper Gastrointestinal Hemorrhage (TEACH Trial): a Randomized Clinical Trial[NCT04786743] | 400 participants (Anticipated) | Interventional | 2021-04-20 | Recruiting | |||
| Endoscopic and Microbiological Assessment of the Effect of Carvedilol Combined With Berberine on GOV in Cirrhosis: a Prospective Cohort Study[NCT04543643] | Phase 3 | 288 participants (Anticipated) | Interventional | 2021-11-01 | Not yet recruiting | ||
| Prospective Cohort Study to Evaluate Long-term Outcomes in Patients With Liver Cirrhosis of Boramae Hospital[NCT01943318] | 500 participants (Actual) | Observational [Patient Registry] | 2013-01-31 | Completed | |||
| Spleen Stiffness Combined With Liver Stiffness Measured by Two-dimensional Shear Wave Elastography for the Screening of High-risk Varices in Patients With Compensated Advanced Chronic Liver Disease (CHESS2004)[NCT04546360] | 300 participants (Anticipated) | Observational [Patient Registry] | 2020-09-08 | Recruiting | |||
| A Novel Algorithm to Stratify Clinical Decompensation Risk in Patients With Compensated Advanced Chronic Liver Disease (CHESS2108)[NCT05100485] | 1,000 participants (Actual) | Observational | 2022-01-01 | Completed | |||
| Multicenter, Randomized, Double-blind, Placebo-controlled Study on the Effectiveness of Treatment With Beta-blockers to Prevent Decompensation of Cirrhosis With Portal Hypertension[NCT01059396] | Phase 4 | 201 participants (Actual) | Interventional | 2010-01-28 | Completed | ||
| CHESS-SAVE Score to Stratify Decompensation Risk in Compensated Advanced Chronic Liver Disease: an International Multicenter Study (CHESS2102)[NCT04975477] | 1,000 participants (Anticipated) | Observational | 2021-07-16 | Not yet recruiting | |||
| Hemodynamic Effect of the Combination of Simvastatin With Non-cardioselective Beta Blockers in Patients With Cirrhosis and Clinically Significant Portal Hypertension[NCT01282385] | Phase 4 | 60 participants (Anticipated) | Interventional | 2011-04-30 | Not yet recruiting | ||
| Danish Carvedilol Study in Portal Hypertension. Carvedilol in the Prevention of Bleeding in Portal Hypertension and Esophageal Varices[NCT00493480] | Phase 3 | 40 participants (Anticipated) | Interventional | 2003-09-30 | Completed | ||
| Pilot Study to Evaluate the Correlation Between ¹³C Methacetin Breath Test (MBT) and HVPG Measurement as a Tool for Identifying Responders to Portal Hypertension Therapy[NCT01851252] | Phase 1 | 19 participants (Actual) | Interventional | 2013-10-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
13 reviews available for carvedilol and Cruveilhier-Baumgarten Syndrome
| Article | Year |
|---|---|
Carvedilol reduces the risk of decompensation and mortality in patients with compensated cirrhosis in a competing-risk meta-analysis.
Topics: Adrenergic beta-Antagonists; Ascites; Carvedilol; Esophageal and Gastric Varices; Humans; Hypertensi | 2022 |
Review article: controversies surrounding the use of carvedilol and other beta blockers in the management of portal hypertension and cirrhosis.
Topics: Adrenergic beta-Antagonists; Ascites; Carvedilol; Esophageal and Gastric Varices; Gastrointestinal H | 2023 |
Carvedilol as the new non-selective beta-blocker of choice in patients with cirrhosis and portal hypertension.
Topics: Adrenergic beta-Antagonists; Ascites; Carvedilol; Esophageal and Gastric Varices; Gastrointestinal H | 2023 |
Pharmacologic Management of Portal Hypertension.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic beta-Antagonists; Anticoagulants; Antihypertensi | 2019 |
Pharmacologic prevention of variceal bleeding and rebleeding.
Topics: Adrenergic beta-Antagonists; Atorvastatin; Carbazoles; Carvedilol; Esophageal and Gastric Varices; G | 2018 |
Systematic review with meta-analysis: the haemodynamic effects of carvedilol compared with propranolol for portal hypertension in cirrhosis.
Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Hemodynamics; Hepatic Veins; Humans; Hypertensi | 2014 |
Pharmacologic management of portal hypertension.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic beta-Antagonists; Angiogenesis Inhibitors; Anti- | 2014 |
Carvedilol for portal hypertension in cirrhosis: systematic review with meta-analysis.
Topics: Antihypertensive Agents; Carbazoles; Carvedilol; Dose-Response Relationship, Drug; Esophageal and Ga | 2016 |
Beta blockers and cirrhosis, 2016.
Topics: Acute Kidney Injury; Adrenergic beta-Antagonists; Ascites; Carbazoles; Carvedilol; Esophageal and Ga | 2017 |
Prevention and treatment of variceal haemorrhage in 2017.
Topics: Adrenergic beta-Antagonists; Anti-Bacterial Agents; Balloon Occlusion; Carbazoles; Carvedilol; Endos | 2017 |
The role of carvedilol in the management of portal hypertension.
Topics: Antihypertensive Agents; Ascites; Benzopyrans; Carbazoles; Carvedilol; Drug Therapy, Combination; Et | 2010 |
Evaluation of carvedilol for the treatment of portal hypertension.
Topics: Adrenergic Antagonists; Carbazoles; Carvedilol; Esophageal and Gastric Varices; Fibrosis; Humans; Hy | 2004 |
Management of portal hypertension.
Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Esophageal and Gastric Varices; Humans; Hyperte | 2004 |
18 trials available for carvedilol and Cruveilhier-Baumgarten Syndrome
| Article | Year |
|---|---|
Assessment of Haemodynamic Response to Nonselective Beta-Blockers in Portal Hypertension by Phase-Contrast Magnetic Resonance Angiography.
Topics: Adrenergic beta-Antagonists; Aged; Aorta, Abdominal; Carbazoles; Carvedilol; Contrast Media; Female; | 2017 |
β blockers to prevent decompensation of cirrhosis in patients with clinically significant portal hypertension (PREDESCI): a randomised, double-blind, placebo-controlled, multicentre trial.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Adult; Aged; Ascites; Carvedilol; Double-Blind Me | 2019 |
β blockers to prevent decompensation of cirrhosis in patients with clinically significant portal hypertension (PREDESCI): a randomised, double-blind, placebo-controlled, multicentre trial.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Adult; Aged; Ascites; Carvedilol; Double-Blind Me | 2019 |
β blockers to prevent decompensation of cirrhosis in patients with clinically significant portal hypertension (PREDESCI): a randomised, double-blind, placebo-controlled, multicentre trial.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Adult; Aged; Ascites; Carvedilol; Double-Blind Me | 2019 |
β blockers to prevent decompensation of cirrhosis in patients with clinically significant portal hypertension (PREDESCI): a randomised, double-blind, placebo-controlled, multicentre trial.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Adult; Aged; Ascites; Carvedilol; Double-Blind Me | 2019 |
β blockers to prevent decompensation of cirrhosis in patients with clinically significant portal hypertension (PREDESCI): a randomised, double-blind, placebo-controlled, multicentre trial.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Adult; Aged; Ascites; Carvedilol; Double-Blind Me | 2019 |
β blockers to prevent decompensation of cirrhosis in patients with clinically significant portal hypertension (PREDESCI): a randomised, double-blind, placebo-controlled, multicentre trial.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Adult; Aged; Ascites; Carvedilol; Double-Blind Me | 2019 |
β blockers to prevent decompensation of cirrhosis in patients with clinically significant portal hypertension (PREDESCI): a randomised, double-blind, placebo-controlled, multicentre trial.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Adult; Aged; Ascites; Carvedilol; Double-Blind Me | 2019 |
β blockers to prevent decompensation of cirrhosis in patients with clinically significant portal hypertension (PREDESCI): a randomised, double-blind, placebo-controlled, multicentre trial.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Adult; Aged; Ascites; Carvedilol; Double-Blind Me | 2019 |
β blockers to prevent decompensation of cirrhosis in patients with clinically significant portal hypertension (PREDESCI): a randomised, double-blind, placebo-controlled, multicentre trial.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Adult; Aged; Ascites; Carvedilol; Double-Blind Me | 2019 |
Effects of carvedilol and propranolol on circulatory regulation and oxygenation in cirrhosis: a randomised study.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic beta-Antagonists; Arteries; Blood Pressure; Bloo | 2014 |
Carvedilol vs. esophageal variceal band ligation in the primary prophylaxis of variceal hemorrhage: a multicentre randomized controlled trial.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic beta-Antagonists; Adult; Carbazoles; Carvedilol; | 2014 |
Acute and 14-day hepatic venous pressure gradient response to carvedilol and nebivolol in patients with liver cirrhosis.
Topics: Aged; Antihypertensive Agents; Benzopyrans; Carbazoles; Carvedilol; Ethanolamines; Female; Humans; H | 2013 |
A Randomized, Multi-Center, Open-Label Study to Evaluate the Efficacy of Carvedilol vs. Propranolol to Reduce Portal Pressure in Patients With Liver Cirrhosis.
Topics: Adult; Antihypertensive Agents; Ascites; Carbazoles; Carvedilol; End Stage Liver Disease; Esophageal | 2016 |
Randomized controlled trial of carvedilol versus variceal band ligation for the prevention of the first variceal bleed.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Carbazoles; Carvedilol; Esophageal and Gastric Varices; Fe | 2009 |
Gastrointestinal bleeding: Carvedilol-the best beta-blocker for primary prophylaxis?
Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Endoscopy; Esophageal and Gastric Varices; Gast | 2009 |
Effect of carvedilol on portal pressure estimated by hepatic vein Doppler ultrasound waveform and damping index in cirrhotic patients.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Blood Flow Velocity; Carbazoles; Carvedilol; Female; Hepat | 2010 |
Carvedilol or propranolol in portal hypertension? A randomized comparison.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Double-Blind Method; Fema | 2012 |
Randomized, controlled trial of carvedilol versus nadolol plus isosorbide mononitrate for the prevention of variceal rebleeding.
Topics: Adult; Antihypertensive Agents; Blood Pressure; Carbazoles; Carvedilol; Chi-Square Distribution; Dru | 2012 |
Randomized comparison of long-term carvedilol and propranolol administration in the treatment of portal hypertension in cirrhosis.
Topics: Antihypertensive Agents; Carbazoles; Carvedilol; Drug Therapy, Combination; Female; Humans; Hyperten | 2002 |
Acute administration of carvedilol is more effective than propranolol plus isosorbide-5-mononitrate in the reduction of portal pressure in patients with viral cirrhosis.
Topics: Antihypertensive Agents; Carbazoles; Carvedilol; Drug Therapy, Combination; Female; Humans; Hyperten | 2004 |
The effects of carvedilol a nonselective beta-blocker on portal hemodynamics in cirrhosis.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Carbazoles; Carvedilol; Female; Hemodynamics; Humans; Hype | 2003 |
Effects of the alpha-/beta-blocking agent carvedilol on hepatic and systemic hemodynamics in patients with cirrhosis and portal hypertension.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Adult; Aged; Blood Pressure; Carbazoles; | 1997 |
Carvedilol, a new nonselective beta-blocker with intrinsic anti- Alpha1-adrenergic activity, has a greater portal hypotensive effect than propranolol in patients with cirrhosis.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Antihypertensive Agents; Blood Pressure; | 1999 |
Haemodynamic effects of acute and chronic administration of low-dose carvedilol, a vasodilating beta-blocker, in patients with cirrhosis and portal hypertension.
Topics: Carbazoles; Carvedilol; Drug Administration Schedule; Female; Hemodynamics; Humans; Hypertension, Po | 2002 |
Acute and 7-day portal pressure response to carvedilol and propranolol in cirrhotics.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Adult; Antihypertensive Agents; Carbazole | 2002 |
24 other studies available for carvedilol and Cruveilhier-Baumgarten Syndrome
| Article | Year |
|---|---|
Clinical Outcomes in Patients with Advanced Chronic Liver Disease and Hepatic Venous Pressure Gradient ≤ 10 mm Hg.
Topics: Carvedilol; Elasticity Imaging Techniques; Humans; Hypertension, Portal; Liver Cirrhosis; Portal Pre | 2022 |
[Transudative chylothorax complicated with liver cirrhosis due to primary biliary cholangitis:case report].
Topics: Aged; Bisoprolol; Carvedilol; Chylothorax; Dyspnea; Female; Heart Failure; Humans; Hypertension, Por | 2022 |
Heart rate variability is associated with disease severity and portal hypertension in cirrhosis.
Topics: Ascites; Carvedilol; Cross-Sectional Studies; Esophageal and Gastric Varices; Heart Rate; Humans; Hy | 2023 |
Carvedilol, probably the β-blocker of choice for everyone with cirrhosis and portal hypertension: But not so fast!
Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Humans; Hypertension, Portal; Liver Cirrhosis; | 2023 |
The Efficacy of Argon Plasma Coagulation versus Carvedilol for Treatment of Portal Hypertensive Gastropathy.
Topics: Argon Plasma Coagulation; Carvedilol; Gastrointestinal Hemorrhage; Humans; Hypertension, Portal; Sto | 2020 |
Individualized Treatment of Gastric Varices in Cirrhotic Portal Hypertension.
Topics: Carvedilol; Esophageal and Gastric Varices; Gastrointestinal Hemorrhage; Humans; Hypertension, Porta | 2019 |
KASL clinical practice guidelines for liver cirrhosis: Varices, hepatic encephalopathy, and related complications.
Topics: Adrenergic beta-Antagonists; Ammonia; Anti-Bacterial Agents; Carvedilol; Disaccharides; Endoscopy, G | 2020 |
CARVEDILOL AS PRIMARY PROPHYLAXIS FOR GASTRIC VARICEAL BLEEDING IN PORTAL HYPERTENSION MODEL IN RATS.
Topics: Adrenergic beta-Antagonists; Animals; Antihypertensive Agents; Carvedilol; Esophageal and Gastric Va | 2020 |
Editorial: Beta blockers and cirrhosis-more than just portal hypertension?
Topics: Adrenergic beta-Antagonists; Carvedilol; Follow-Up Studies; Humans; Hypertension, Portal; Liver Cirr | 2021 |
Austrian consensus guidelines on the management and treatment of portal hypertension (Billroth III).
Topics: Austria; Carbazoles; Carvedilol; Comorbidity; Early Medical Intervention; Esophageal and Gastric Var | 2017 |
Austrian consensus guidelines on the management and treatment of portal hypertension (Billroth III).
Topics: Austria; Carbazoles; Carvedilol; Comorbidity; Early Medical Intervention; Esophageal and Gastric Var | 2017 |
Austrian consensus guidelines on the management and treatment of portal hypertension (Billroth III).
Topics: Austria; Carbazoles; Carvedilol; Comorbidity; Early Medical Intervention; Esophageal and Gastric Var | 2017 |
Austrian consensus guidelines on the management and treatment of portal hypertension (Billroth III).
Topics: Austria; Carbazoles; Carvedilol; Comorbidity; Early Medical Intervention; Esophageal and Gastric Var | 2017 |
A Patient with Dilated Cardiomyopathy and Portal Hypertension: Which Beta-Blocker to Use?
Topics: Adrenergic beta-Antagonists; Carbazoles; Cardiomyopathy, Dilated; Carvedilol; Clinical Decision-Maki | 2017 |
Carvedilol for reducing portal pressure in primary prophylaxis of variceal bleeding: a dose-response study.
Topics: Antihypertensive Agents; Carvedilol; Dose-Response Relationship, Drug; Esophageal and Gastric Varice | 2018 |
Editorial: optimal dose of carvedilol in portal hypertension…nearly there. Authors' reply.
Topics: Carvedilol; Humans; Hypertension, Portal; Propanolamines | 2018 |
Editorial: optimal dose of carvedilol in portal hypertension…nearly there.
Topics: Carvedilol; Esophageal and Gastric Varices; Gastrointestinal Hemorrhage; Humans; Hypertension, Porta | 2018 |
Non-invasive response prediction in prophylactic carvedilol therapy for cirrhotic patients with esophageal varices.
Topics: Adrenergic beta-Antagonists; Carvedilol; Chemoprevention; Clinical Decision Rules; Elasticity Imagin | 2019 |
Non-invasive response prediction in prophylactic carvedilol therapy for cirrhotic patients with esophageal varices.
Topics: Adrenergic beta-Antagonists; Carvedilol; Chemoprevention; Clinical Decision Rules; Elasticity Imagin | 2019 |
Non-invasive response prediction in prophylactic carvedilol therapy for cirrhotic patients with esophageal varices.
Topics: Adrenergic beta-Antagonists; Carvedilol; Chemoprevention; Clinical Decision Rules; Elasticity Imagin | 2019 |
Non-invasive response prediction in prophylactic carvedilol therapy for cirrhotic patients with esophageal varices.
Topics: Adrenergic beta-Antagonists; Carvedilol; Chemoprevention; Clinical Decision Rules; Elasticity Imagin | 2019 |
Carvedilol Ameliorates Intrahepatic Angiogenesis, Sinusoidal Remodeling and Portal Pressure in Cirrhotic Rats.
Topics: Angiogenesis Inducing Agents; Animals; Capillaries; Carvedilol; Endothelial Cells; Fibronectins; Hum | 2018 |
Carvedilol improves liver cirrhosis in rats by inhibiting hepatic stellate cell activation, proliferation, invasion and collagen synthesis.
Topics: Administration, Oral; Alanine Transaminase; Animals; Antioxidants; Aspartate Aminotransferases; Carb | 2019 |
Secondary prophylaxis for variceal bleeding: carvedilol vs. propranolol.
Topics: Adrenergic beta-Antagonists; Blood Pressure; Carbazoles; Carvedilol; Drug Monitoring; Esophageal and | 2017 |
Carvedilol versus variceal band ligation for prevention of the first variceal bleed.
Topics: Carbazoles; Carvedilol; Esophageal and Gastric Varices; Gastrointestinal Hemorrhage; Humans; Hyperte | 2010 |
Carvedilol for portal hypertension in patients with cirrhosis.
Topics: Antihypertensive Agents; Carbazoles; Carvedilol; Humans; Hypertension, Portal; Liver Cirrhosis; Male | 2010 |
Non-selective β-blockers improve the correlation of liver stiffness and portal pressure in advanced cirrhosis.
Topics: Adrenergic beta-Antagonists; Adult; Carbazoles; Carvedilol; Elasticity; Elasticity Imaging Technique | 2012 |
Effect of carvedilol on portal hypertension depends on the degree of endothelial activation and inflammatory changes.
Topics: Adrenergic beta-Antagonists; Biomarkers; Carbazoles; Carvedilol; E-Selectin; Endothelium, Vascular; | 2006 |
Acute haemodynamic changes after oral carvedilol, a vasodilating beta-blocker, in patients with cirrhosis.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Azygos Vein; Blood Flow Velocity; Blood Pressure; | 1996 |
An advance in the treatment of portal hypertension?
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Humans; Hypertens | 2000 |